[go: up one dir, main page]

EP4043455A4 - Composé bicyclique qui agit comme régulateur de la protéine crbn - Google Patents

Composé bicyclique qui agit comme régulateur de la protéine crbn Download PDF

Info

Publication number
EP4043455A4
EP4043455A4 EP20862879.2A EP20862879A EP4043455A4 EP 4043455 A4 EP4043455 A4 EP 4043455A4 EP 20862879 A EP20862879 A EP 20862879A EP 4043455 A4 EP4043455 A4 EP 4043455A4
Authority
EP
European Patent Office
Prior art keywords
bicyclic compound
protein regulator
crbn protein
crbn
regulator
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP20862879.2A
Other languages
German (de)
English (en)
Other versions
EP4043455A1 (fr
Inventor
Yunfu Luo
Maoyi LEI
Yu Xu
Junmiao LI
Guoli Zhang
Jinghong DONG
Shuhui Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medshine Discovery Inc
Original Assignee
Medshine Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medshine Discovery Inc filed Critical Medshine Discovery Inc
Publication of EP4043455A1 publication Critical patent/EP4043455A1/fr
Publication of EP4043455A4 publication Critical patent/EP4043455A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
EP20862879.2A 2019-09-12 2020-09-14 Composé bicyclique qui agit comme régulateur de la protéine crbn Withdrawn EP4043455A4 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201910867013 2019-09-12
CN201910866549 2019-09-12
CN201910865754 2019-09-12
PCT/CN2020/115126 WO2021047674A1 (fr) 2019-09-12 2020-09-14 Composé bicyclique qui agit comme régulateur de la protéine crbn

Publications (2)

Publication Number Publication Date
EP4043455A1 EP4043455A1 (fr) 2022-08-17
EP4043455A4 true EP4043455A4 (fr) 2023-09-20

Family

ID=74866585

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20862879.2A Withdrawn EP4043455A4 (fr) 2019-09-12 2020-09-14 Composé bicyclique qui agit comme régulateur de la protéine crbn

Country Status (5)

Country Link
US (1) US11905276B2 (fr)
EP (1) EP4043455A4 (fr)
JP (1) JP7209897B2 (fr)
CN (1) CN114401962B (fr)
WO (1) WO2021047674A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230158152A1 (en) * 2020-03-17 2023-05-25 Medshine Discovery Inc. Proteolysis regulator and method for using same
CN117751112A (zh) * 2021-07-19 2024-03-22 南京明德新药研发有限公司 杂芳-3-哌啶二酮类化合物及其应用
CN116535423B (zh) * 2022-01-26 2025-06-06 武汉誉祥医药科技有限公司 抑制/诱导降解egfr激酶的化合物及其药物组合物和应用
AR129422A1 (es) * 2022-05-25 2024-08-21 Univ Leuven Kath Nuevos derivados para tratar trastornos mediados por trpm3
CN115403544B (zh) * 2022-09-16 2024-05-31 台州永健医药科技有限公司 一种丹酚酸c的制备方法
EP4626880A1 (fr) * 2022-11-28 2025-10-08 Shanghai Degron Biomedical Technology Co., Ltd. Composés pour la modulation de l'hur (elavl1)
WO2025232888A1 (fr) * 2024-05-10 2025-11-13 Shanghai Degron Biomedical Technology Co., Ltd. Agents de dégradation de wee1 et leurs utilisations

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018144649A1 (fr) * 2017-01-31 2018-08-09 Arvinas, Inc. Ligands de céréblon et composés bifonctionnels les contenant
WO2020048548A1 (fr) * 2018-09-07 2020-03-12 正大天晴药业集团股份有限公司 Composés tricycliques agissant sur des protéines crbn
WO2020048546A1 (fr) * 2018-09-07 2020-03-12 南京明德新药研发有限公司 Composé de pipéridine dione substitué tricyclique
WO2021047627A1 (fr) * 2019-09-12 2021-03-18 南京明德新药研发有限公司 Composé cyclique fusionné capable de dégrader une protéine et son utilisation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5647615B2 (ja) * 2008-11-14 2015-01-07 コンサート ファーマシューティカルズ インコーポレイテッド 置換ジオキソピペリジニルフタルイミド誘導体
KR20150054962A (ko) * 2012-09-10 2015-05-20 셀진 코포레이션 국소 진행성 유방암의 치료방법
BR112018067775B1 (pt) * 2016-03-04 2024-02-15 Vanderbilt University Compostos inibidores de mcl-1 indol substituídos, composição farmacêutica compreendendo ditos compostos e usos terapêuticos dos mesmos
WO2020048547A1 (fr) * 2018-09-07 2020-03-12 南京明德新药研发有限公司 Composé pipéridinedione tricyclique substitué par furane

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018144649A1 (fr) * 2017-01-31 2018-08-09 Arvinas, Inc. Ligands de céréblon et composés bifonctionnels les contenant
WO2020048548A1 (fr) * 2018-09-07 2020-03-12 正大天晴药业集团股份有限公司 Composés tricycliques agissant sur des protéines crbn
WO2020048546A1 (fr) * 2018-09-07 2020-03-12 南京明德新药研发有限公司 Composé de pipéridine dione substitué tricyclique
EP3848367A1 (fr) * 2018-09-07 2021-07-14 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Composés tricycliques agissant sur des protéines crbn
EP3848363A1 (fr) * 2018-09-07 2021-07-14 Medshine Discovery Inc. Composé de pipéridine dione substitué tricyclique
WO2021047627A1 (fr) * 2019-09-12 2021-03-18 南京明德新药研发有限公司 Composé cyclique fusionné capable de dégrader une protéine et son utilisation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2021047674A1 *

Also Published As

Publication number Publication date
US11905276B2 (en) 2024-02-20
EP4043455A1 (fr) 2022-08-17
JP7209897B2 (ja) 2023-01-20
CN114401962A (zh) 2022-04-26
WO2021047674A1 (fr) 2021-03-18
US20230348441A1 (en) 2023-11-02
CN114401962B (zh) 2024-05-24
JP2022537605A (ja) 2022-08-26

Similar Documents

Publication Publication Date Title
EP4043455A4 (fr) Composé bicyclique qui agit comme régulateur de la protéine crbn
KR102795633B9 (ko) 넥틴-4에 대해 특이적인 비사이클릭 펩타이드 리간드
DK4464721T3 (da) Bicykliske heterotandem-peptidkomplekser
DK3956033T3 (da) Bicykliske forbindelser
HUE062777T2 (hu) SARS-CoV-2 elleni antitestek
IL283873A (en) Bicyclic peptide ligands specific for mt1-mmp
EP3950061A4 (fr) Conjugué anticorps-dérivé de pyrrolobenzodiazépine
KR102763158B9 (ko) 최적화된 항tl1a 항체
DK4083038T3 (da) Pyridazinylthiazolcarboxamidforbindelse
IL283874A (en) Bicyclic peptide ligands specific for mt1-mmp
PL3939747T3 (pl) Gwoździarka
EP4245713A4 (fr) Agv
CR20230573A (es) ANTICUERPOS ANTI-SIRP-alfa
IL290878A (en) Protein based cannabis compositions
IL288097A (en) Optimized cannabinoid synthase polypeptides
EP3822276A4 (fr) Composé hétérocyclique utilisé en tant qu'inhibiteur de trk
DK4214240T3 (da) Anti-ccr8-antistoffer
EP4031954A4 (fr) Pré-régulateur pour un ldo
EP4257597A4 (fr) Composés polypeptidiques modifiés par lactame
DK3770046T3 (da) Førerløst transportsystem
EP4049684A4 (fr) Anticorps humanisé marqué par ri
EP3744016C0 (fr) Priorité de sélection de faisceau
EP4392455A4 (fr) Anticorps anti-cd-25
IL310245A (en) Anti-hla-g antibodies
EP3885197A4 (fr) Véhicule autonome

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220412

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20230821

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/02 20060101ALI20230814BHEP

Ipc: A61P 35/00 20060101ALI20230814BHEP

Ipc: A61K 31/445 20060101ALI20230814BHEP

Ipc: A61K 31/42 20060101ALI20230814BHEP

Ipc: C07D 491/04 20060101ALI20230814BHEP

Ipc: C07D 491/00 20060101ALI20230814BHEP

Ipc: C07D 498/04 20060101ALI20230814BHEP

Ipc: C07D 413/14 20060101ALI20230814BHEP

Ipc: C07D 413/04 20060101AFI20230814BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20240531

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20241001